Hennion & Walsh Asset Management, Inc. Cyma Bay Therapeutics, Inc. Transaction History

Hennion & Walsh Asset Management, Inc.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 10, 2024	BUY	$12.63 - $24.47 $69,111 - $133,899	5,472 Added 7.51%	78,311 $1.85 Million
Q3 2023 Oct 27, 2023	BUY	$10.86 - $17.62 $373,616 - $606,180	34,403 Added 89.51%	72,839 $1.09 Million
Q2 2023 Aug 09, 2023	BUY	$7.47 - $10.95 $287,116 - $420,874	38,436 New	38,436 $421,000

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Hennion & Walsh Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Hennion & Walsh Asset Management, Inc. with notifications on news.